PL4356969T3 - Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusami - Google Patents
Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusamiInfo
- Publication number
- PL4356969T3 PL4356969T3 PL23217305.4T PL23217305T PL4356969T3 PL 4356969 T3 PL4356969 T3 PL 4356969T3 PL 23217305 T PL23217305 T PL 23217305T PL 4356969 T3 PL4356969 T3 PL 4356969T3
- Authority
- PL
- Poland
- Prior art keywords
- orthomyxoviral
- infections
- treatment
- compounds useful
- pyridazinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4356969T3 true PL4356969T3 (pl) | 2025-10-20 |
Family
ID=59923494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23217305.4T PL4356969T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusami |
| PL17771587T PL3504214T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17771587T PL3504214T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11098051B2 (https=) |
| EP (4) | EP3848372B1 (https=) |
| JP (3) | JP7221861B2 (https=) |
| CN (2) | CN113683614B (https=) |
| AR (1) | AR109438A1 (https=) |
| CA (1) | CA3035302A1 (https=) |
| DK (1) | DK4356969T3 (https=) |
| ES (3) | ES2859510T3 (https=) |
| FI (1) | FI4356969T3 (https=) |
| HR (1) | HRP20250885T1 (https=) |
| HU (1) | HUE072776T2 (https=) |
| JO (1) | JOP20170169A1 (https=) |
| LT (1) | LT4356969T (https=) |
| MX (1) | MX383124B (https=) |
| PL (3) | PL4356969T3 (https=) |
| PT (3) | PT3848372T (https=) |
| SI (3) | SI3504214T1 (https=) |
| TW (3) | TWI803467B (https=) |
| UY (2) | UY40872A (https=) |
| WO (1) | WO2018042303A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015038655A1 (en) * | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| AU2016374416A1 (en) | 2015-12-15 | 2018-06-14 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| CN111848615B (zh) | 2018-01-17 | 2022-05-17 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及包含其的抗流感病毒药物组合物 |
| KR20230031990A (ko) | 2018-02-28 | 2023-03-07 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
| CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
| MX2021004182A (es) * | 2018-10-10 | 2021-09-08 | Janssen Biopharma Inc | Inhibidores macrocíclicos de endonucleasa de la gripe. |
| CN111909174B (zh) | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的晶型及制备方法和应用 |
| CN118480041A (zh) * | 2019-12-23 | 2024-08-13 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
| WO2024228401A1 (ja) * | 2023-05-02 | 2024-11-07 | 国立大学法人 大分大学 | 新型コロナウイルス感染症の処置または予防用医薬としての置換三環式複素環化合物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2225112A (en) | 1938-07-09 | 1940-12-17 | Wright Aeronautical Corp | Air cleaner |
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| BR0211750A (pt) | 2001-08-10 | 2004-10-13 | Shionogi & Co | Agente antiviral |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| US9238657B2 (en) | 2008-10-31 | 2016-01-19 | Shionogi & Co., Ltd. | Cephalosporin having catechol group |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| LT2444400T (lt) | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Pakeistasis policiklinis karbamoilpiridono darinys |
| US8541418B2 (en) | 2009-12-23 | 2013-09-24 | Elan Pharmaceutical, Inc. | Inhibitors of polo-like kinase |
| TW201201813A (en) | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| MX2013003139A (es) | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| EP2774928B1 (en) * | 2011-10-12 | 2017-08-30 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| AU2013318779B2 (en) | 2012-09-20 | 2016-07-28 | Celltrion, Inc. | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same |
| CN104918942A (zh) | 2013-01-08 | 2015-09-16 | 萨维拉制药有限公司 | 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 |
| NZ716822A (en) | 2013-08-21 | 2017-10-27 | Alios Biopharma Inc | Antiviral compounds |
| CN105530946A (zh) | 2013-09-11 | 2016-04-27 | 南加利福尼亚大学 | 具有高度表达的fas配体的干细胞组合物 |
| WO2015038655A1 (en) | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| ES2724581T3 (es) | 2013-09-12 | 2019-09-12 | Janssen Biopharma Inc | Compuestos de piridazinona y usos de los mismos |
| WO2016005330A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| WO2016145103A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| WO2017156407A1 (en) | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
| EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
| CN111848615B (zh) | 2018-01-17 | 2022-05-17 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及包含其的抗流感病毒药物组合物 |
| CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| KR20200127177A (ko) | 2018-02-28 | 2020-11-10 | 니뽄 다바코 산교 가부시키가이샤 | 포화 환 축합 디히드로피리미디논 또는 디히드로트리아지논 화합물 및 그의 의약 용도 |
| RU2020131012A (ru) | 2018-02-28 | 2022-03-28 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени |
| WO2019167981A1 (ja) | 2018-02-28 | 2019-09-06 | 日本たばこ産業株式会社 | ４－メチルジヒドロピリミジノン化合物及びその医薬用途 |
| KR20230031990A (ko) | 2018-02-28 | 2023-03-07 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
-
2017
- 2017-08-24 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en not_active Ceased
- 2017-08-25 FI FIEP23217305.4T patent/FI4356969T3/fi active
- 2017-08-25 MX MX2019002438A patent/MX383124B/es unknown
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-25 HU HUE23217305A patent/HUE072776T2/hu unknown
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 ES ES23217305T patent/ES3042460T3/es active Active
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 CN CN202110956692.7A patent/CN113683614B/zh active Active
- 2017-08-25 LT LTEP23217305.4T patent/LT4356969T/lt unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 DK DK23217305.4T patent/DK4356969T3/da active
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-25 EP EP25187556.3A patent/EP4640279A3/en active Pending
- 2017-08-25 PL PL23217305.4T patent/PL4356969T3/pl unknown
- 2017-08-25 HR HRP20250885TT patent/HRP20250885T1/hr unknown
- 2017-08-25 EP EP23217305.4A patent/EP4356969B1/en active Active
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 SI SI201731493T patent/SI3848372T1/sl unknown
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 SI SI201731620T patent/SI4356969T1/sl unknown
- 2017-08-25 PT PT232173054T patent/PT4356969T/pt unknown
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 ES ES20210329T patent/ES2974494T3/es active Active
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/pl unknown
- 2017-08-28 UY UY0001040872A patent/UY40872A/es not_active Application Discontinuation
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-28 TW TW113134345A patent/TW202517646A/zh unknown
- 2017-08-28 TW TW112101158A patent/TWI869757B/zh active
- 2017-08-28 UY UY0001037378A patent/UY37378A/es active IP Right Grant
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es active IP Right Grant
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja not_active Withdrawn
-
2024
- 2024-06-13 US US18/743,020 patent/US20250011334A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009843A patent/JP2025081322A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4356969T3 (pl) | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu zakażenia ortomyksowirusami | |
| HUS2500039I1 (hu) | Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra | |
| IL269354A (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| EP3922634C0 (en) | SUBSTITUTED PYRROLIZINE COMPOUNDS AND THEIR APPLICATIONS | |
| SI3347352T1 (sl) | Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV | |
| MA45192A (fr) | Traitement d'association | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| HUE053704T2 (hu) | 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére | |
| DK3511328T3 (da) | Organiske monobactam-forbindelser til behandling af bakterieinfektioner | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| HRP20251450T1 (hr) | Beta-d-2'-dezoksi-2'alfa-fluoro-2'-beta-c-supstituirani-2-modificirani-n6-supstituirani purinski nukleotidi za liječenje hcv | |
| IL247111A0 (en) | Preventive or therapeutic agent for kidney disease | |
| IL271863B (en) | Compounds and use thereof for the treatment of microbial infections | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| EP3548045C0 (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF UROGENITAL INFECTION | |
| EP3661919A4 (en) | SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| CY2024037I2 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| EP3523284A4 (en) | NUCLEOBASE DIVALENT COMPOUNDS AND THEIR USES | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
| EP3493823C0 (en) | POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION | |
| DK3423060T3 (da) | Imatinib til anvendelse til behandling af slagtilfælde | |
| DK3442558T3 (da) | Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis |